Search
Aquestive Therapeutics Inc
AQSTAdd to Watchlist
4.060USD
-0.550-11.93%
Close 10-15 16:00（ET）
509.41MMarket Cap
LossP/E TTM
Aquestive Therapeutics Inc (AQST) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Aquestive Therapeutics Inc in the past month.
Buy
2 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
9.333USD+99.86%
AQST Analyst Recommendation Trends
In the current month, AQST has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AQST average Analyst price target in the last month is 9.333.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
2
2
2
2
2
2
2
7
7
7
7
7
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
9
9
9
AQST Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
18
3
1
0
32
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, AQST EPS is projected to reach -0.116 in FY2026Q3, following reported EPS of -0.183 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.13
-0.14
-0.10
-0.12
-0.14
Actual
-0.26
-0.07
-0.18
--
--
Surprise
-96.88%
+52.09%
-77.03%
--
--
FAQs
What is Aquestive Therapeutics Inc's expected revenue for the next quarter?
Aquestive Therapeutics Inc's expected revenue is 11.02M.
What is Aquestive Therapeutics Inc's price target?
Analysts forecast that Aquestive Therapeutics Inc's price target is USD 9.33, with the highest forecast at USD 11.00 and the lowest forecast at USD 6.00.
How have Aquestive Therapeutics IncAQST's recent earnings per share performed?
The market expectation was USD -0.18, while Aquestive Therapeutics IncAQST's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Aquestive Therapeutics Inc?
Based on the ratings of Aquestive Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.